Lupin Secures USFDA Approval for Raltegravir Tablets, Gains 180-Day Generic Exclusivity

Unknown Apr 02, 2026 2,300 Views

Lupin Ltd. has received approval from the United States Food and Drug Administration for its Raltegravir Tablets USP, 600 mg, marking a significant milestone in its pharmaceutical portfolio. The approval allows Lupin to market a generic equivalent of Isentress HD, a widely used antiretroviral med...